Therapeutic Asset Ratings
3,272 results matching 1 filter
91,583 assets · 7,906 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
PI3K/MTOR INHIBITOR LY3023414
Central Nervous System Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Rhabdoid Tumor
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Soft Tissue Sarcoma
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Refractory Malignant Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
PI3K/MTOR INHIBITOR LY3023414
Wilms Tumor
National Cancer Institute (NCI)
P2
B
(57)
Selumetinib
Central Nervous System Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Selumetinib
Neuroblastoma
National Cancer Institute (NCI)
P2
B
(57)
Selumetinib
Primary Peritoneal Carcinoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Langerhans Cell Histiocytosis
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Malignant Glioma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Rhabdomyosarcoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Ependymoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Ewing Sarcoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Glioma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Hepatoblastoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Malignant Germ Cell Tumor
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Medulloblastoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Neuroblastoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Osteosarcoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Peripheral Primitive Neuroectodermal Tumor
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Central Nervous System Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Refractory Malignant Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Wilms Tumor
National Cancer Institute (NCI)
P2
B
(57)
Tiragolumab
Refractory Malignant Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Atezolizumab
Fallopian Tube Serous Adenocarcinoma
National Cancer Institute (NCI)
P2/3
B
(57)
Showing 851 to 875 of 3,272 assets
Previous
Page 35 of 131
Next